Ludwig prepares major patent application
SPARKS, NV / ACCESSWIRE / September 20, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, a leading innovator of genetic inflammatory biomarkers for the diagnosis and treatment of chronic diseases, is pleased to announce that the company has entered into discussions with Emerson Urology Associates, Concord, MA regarding the initiation of a clinical trial to evaluate the response of bladder cancer patients to BCG immunotherapy. A confidentiality agreement has been signed with Dr. John Libertino, MD, director of Emerson Urology Associates.
Bladder cancer is the sixth most common cancer in the United States and the ninth most common worldwide. Bladder cancer makes up about 5% of new cancers in the US each year, especially in older people. By 2021, an estimated 83,000 new cases will be diagnosed and about 17,000 deaths in the US alone. The standard treatment for patients with bladder cancer that has invaded muscle tissue includes cisplatin-based chemotherapy followed by surgical removal of the bladder or radiation therapy and concurrent chemotherapy.
An additional treatment approach is immunotherapy, a class of treatments that uses a person’s own immune system to kill cancer cells. Bacillus Calmette-Guérin (BCG) is a cancer vaccine that uses weakened bacteria to boost the immune system. BCG has received approval from the US FDA for the treatment of early-stage bladder cancer.
The goal of the joint research program between Ludwig Enterprises and Emerson Urology Associates is to use Ludwig’s proprietary genetic inflammatory markers to study patients with early-stage superficial bladder cancer and assess the therapeutic response to BCG immunotherapy.
Ludwig’s patented panel for genetic inflammatory biomarkers is currently being filed with the US Patent Office.
“This innovative research study has the potential to create a predictive model for early-stage cancer to occur at a presymptomatic stage and to show which patients will respond to specific cancer chemotherapy,” said Dr. Marvin S. Hausman MD, chairman of the scientific advisory board of Ludwig. (SAB). “Essentially, Ludwig has developed a proprietary language that has the potential to capture a snapshot of disease and the body’s response to treatment.”
“Early diagnosis of urologic cancer and the ability to predict cancer response has been a dream of mine for a long time,” says Dr. John Libertino, MD, director of Emerson Urology Associates. I look forward to the clinical results of this. collaborative relationship.”
About Ludwig Enterprises, Inc.: Ludwig is an innovative technology and health-related company that uses inflammatory genetic markers to diagnose, diagnose, and assess pre- and post-treatment responses. Initial clinical programs include, but are not limited to, heart disease, preeclampsia, breast cancer, colon cancer, and bladder cancer.
About Emerson Urology Associates: Our urologists provide comprehensive medical and surgical services for urological conditions and provide the most advanced diagnostic and treatment expertise available today.
Forward-looking statements in this press release are made under the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.’s forward-looking statements. are no guarantee of future performance. This press release contains forward-looking statements regarding the future level of business for the parties. These statements are necessarily subject to risks and uncertainties. Actual results could differ materially from those projected in these forward-looking statements because of certain risk factors that could cause results to differ materially from estimated results. Management cautions that any statements about future results of operations are necessarily subject to risks, uncertainties and events beyond the control of Ludwig Enterprises, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, maintain and complete projects and changes in products and competition.
SOURCE: Ludwig Enterprises, Inc.
Check out the source version at accesswire.com: